Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
WilmerHale has played a leading role in shaping the rules that govern the financial services industry in the United States.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

Beam Therapeutics Inc. (Nasdaq: BEAM) announced that it has entered into a strategic financing agreement with Sixth Street Lending Partners as agent, which provides for a senior secured term loan facility of up to $500 million, consisting of an initial draw of $100 million and potential additional draws of $400 million upon meeting certain requirements. The closing of the term loan facility occurred on February 24, 2026. Beam Therapeutics is a biotechnology company developing precision genetic medicines through base editing. 

WilmerHale advised Beam Therapeutics on the transaction. 

The WilmerHale team consisted of George Shuster, Nathan Moore, Alex Dean, Michael Katz, Jane Cha and Rebecca Beames, with assistance from Cynthia Mazareas, Steven Barrett, Meghan Walsh, Stephanie Leopold, Tim Silva, Annaka Merrick and Lorri Strizich.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link. (The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel